Delivery Order #36C10X26N0165

Fulgent Therapeutics Delivery Order for Germline PGX Molecular Testing

This award is a delivery order under an existing indefinite delivery vehicle, continuing the collaboration between the Department of Veterans Affairs (VA) and Fulgent Therapeutics LLC, a company specializing in advanced genetic testing services. The contract procures germline pharmacogenomic (PGX) molecular testing, which plays a crucial role in personalized medicine by informing diagnostic and therapeutic decisions, particularly in oncology and medical genetics. It ensures sustained access to specialized genetic testing at VA healthcare sites, supporting improved patient outcomes through precise identification of genetic markers related to drug response. The scope of work involves delivering germline molecular testing services that enable tailored treatment plans and enhance medical care quality. This award follows a competitive acquisition approach as a supplemental agreement to a larger IDV contract that encompasses national genetic testing programs. It builds upon prior performance under a significant VA contract aimed at broad national coverage for genetics services. The contract period covers one year, underscoring an ongoing commitment to maintaining and expanding vital testing capabilities. Key dates align with a mid-2026 to mid-2027 timeframe for service delivery. While specifics on subcontractors and solicitation details are not disclosed, this award marks a strategic step in advancing VA's genomics-enabled healthcare initiatives.

Description

GERMLINE PGX MOLECULAR TESTING

View original record